The purpose of the present invention is to provide a novel hair growth promoter. The features of the present invention for solving the problem are as follows. 1. A hair growth promoter containing an extract of yellow strawberry guava fruit as an active ingredient. 2. An agent for promoting vascular endothelial cell growth factor production, containing an extract of yellow strawberry guava fruit as an active ingredient. 3. A food or drink composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 4. A pharmaceutical composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 5. A hair cosmetic composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 6. A topical skin preparation composition for promoting hair growth, containing the hair growth promoter as an active ingredient. 7. A hair growth promoter for use in oral administration, containing an aqueous ethanol extract of yellow strawberry guava fruit as an active ingredient.
A 5α-reductase inhibitor contains saw palmetto extract and seaberry extract as an active ingredient in a synergistic compounding ratio, wherein the compounding ratio by weight of the saw palmetto extract and the seaberry extract is 3:1˜2. The 5α-reductase inhibitor containing the saw palmetto extract and seaberry extract or just the seaberry extract as a 5α-reductase inhibitor can be administered to the human body in order to inhibit 5α-reductase. The 5α-reductase inhibitor is useful as a prostate enlargement inhibitor, an androgenic alopecia inhibitor, and an acne prevention and amelioration agent. The 5α-reductase inhibitor can be part of a food or drink composition or a cosmetic composition.
Provided is a new immunostimulant. The features of the present invention for solving the problem are as follows. 1. An agent for promoting production of IL-6 in dendritic cells, the agent comprising, as an active ingredient, at least one selected from GlcCer[d18:2(4E,8Z)/18:0], GlcCer[d18:2(4E,8Z)/26:0], GlcCer[t18:1(8Z)/20:0], and Cer[t18:0/22:0]. 2. The agent for promoting production of IL-6 according to 1. described above, the agent being characterized in that the production of IL-6 is carried out through binding to TLR2 and/or TLR4. 3. An agent for causing proliferation of helper T-cells by dendritic cells, the agent comprising, as an active ingredient, at least one selected from GlcCer[d18:2(4E,8Z)/18:0] and GlcCer[d18:2(4E,8Z)/26:0]. 4. An activator for presenting an antigen to dendritic cells, the activator comprising, as an active ingredient, GlcCer[d18:2(4E,8Z)/18:0]. 5. An immunostimulant comprising, as an active ingredient, at least one selected from GlcCer[d18:2(4E,8Z)/18:0], GlcCer[d18:2(4E,8Z)/26:0], GlcCer[t18:1(8Z)/20:0], and Cer[t18:0/22:0].
The present invention addresses the problem of providing: a novel compound; and a use of the compound. The features of the present invention for solving the problem are as follows. 1. A compound represented by chemical formula (1). 2. A compound represented by chemical formula (2). 3. A transepidermal water loss reducing agent containing the compound mentioned in 1 or 2 as an active ingredient. 4. A moisturizing agent containing the compound mentioned in 1 or 2 as an active ingredient. 5. An agent for promoting the production of interleukin-6 in dendritic cells, which contains the compound mentioned in 1 or 2 as an active ingredient. 6. An immunostimulant containing the compound mentioned in 1 or 2 as an active ingredient. 7. A method for producing the compound mentioned in 1 or 2, the method being characterized by including a step for isolating the compound from an extract from rice bran.
C07H 15/10 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide contenant des liaisons non saturées carbone-carbone
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
A23G 3/36 - Sucreries, confiseries ou massepainProcédés pour leur fabrication caractérisés par la composition
A23G 4/06 - Chewing-gum caractérisé par la composition
A23L 29/281 - Protéines, p. ex. gélatine ou collagène
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p. ex. bambou, blé ou canne à sucre
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/16 - Émollients ou protecteurs, p. ex. contre les radiations
Camellia sinensis; variety name: TRFK306) containing 1,2-di-O-galloyl-4,6-O—(S)-hexahydroxydiphenoyl-β-D-glucose (GHG). Then, an effective amount of the purple tea extract is administered to a body of a human being engaged in intensive exercise to reduce muscle damage associated with the intensive exercise.
A61K 36/82 - Theaceae (famille du théier), p. ex. camélia
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
6.
Method of administering seaberry and saw palmetto extracts to inhibit 5α-reductase activity
A 5α-reductase inhibitor contains saw palmetto extract and seaberry extract as an active ingredient in a synergistic compounding ratio, wherein the compounding ratio by weight of the saw palmetto extract and the seaberry extract is 3:1˜2. The 5α-reductase inhibitor containing the saw palmetto extract and seaberry extract or just the seaberry extract as a 5α-reductase inhibitor can be administered to the human body in order to inhibit 5α-reductase. The 5α-reductase inhibitor is useful as a prostate enlargement inhibitor, an androgenic alopecia inhibitor, and an acne prevention and amelioration agent. The 5α-reductase inhibitor can be part of a food or drink composition or a cosmetic composition.
Camellia sinensis, variety name: TRFK306. An effective amount of the GHG can be administered to a cell to activate the AMPK. Drinks, foods, and cosmetics can have the GHG as an active ingredient.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
[Problem] To provide a 5α-reductase inhibitor which contains a novel component as an active ingredient. [Solution] The features of the present invention are as follows. 1. A 5α-reductase inhibitor containing a sea berry extract as an active ingredient. 2. A 5α-reductase inhibitor containing, as active ingredients, a sea berry extract and a saw palmetto extract at such a blend ratio that a synergic effect can be exerted. 3. The 5α-reductase inhibitor according to the above-mentioned item 2, characterized in that the weight-based mixing ratio between the saw palmetto extract and the sea berry extract (i.e., (saw palmetto extract):(sea berry extract)) is (3 to 1):(1 to 2). 4. A prostatic hyperplasia-preventing agent containing a 5α-reductase inhibitor as recited in any one of the above-mentioned items 1 to 3 as an active ingredient. 5. An androgenic alopecia-preventing agent containing a 5α-reductase inhibitor as recited in any one of the above-mentioned items 1 to 3 as an active ingredient. 6. An acne-preventing/ameliorating agent containing a 5α-reductase inhibitor as recited in any one of the above-mentioned items 1 to 3 as an active ingredient.
A23G 3/48 - Sucreries, confiseries ou massepainProcédés pour leur fabrication caractérisés par la composition contenant des végétaux ou des parties de ceux-ci, p. ex. des fruits, des graines, des extraits
A23G 4/06 - Chewing-gum caractérisé par la composition
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietary and nutritional supplements; dietary and nutritional
supplements containing glycosphingolipid of rice origin or
containing ceramide derived from glycosphingolipid of rice
origin, in the form of powder, granule, liquid, capsule
(including hard capsule, soft capsule, microcapsule or the
like) and tablet; dietary and nutritional supplements with a
cosmetic effect.
[Problem] The purpose of the present invention is to provide a novel AMPK activator. [Solution] The technical features of the present invention for solving the above problem are as follows. 1. An AMPK activator having 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-b-D-glucose ("GHG" hereinafter) as an active ingredient. 2. An AMPK activator comprising a GHG-containing composition that includes GHG as an active ingredient. 3. An AMPK activator comprising a GHG-containing composition derived from Kenyan purple tea (scientific name: Camellia sinensis, variety name TRFK306).
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
purple tea extract for use in the manufacture of foods, beverages and dietary supplements extract of purple tea sold as a component ingredient of dietary supplements
[Problem] The purpose of the present invention is to provide a novel ECM cycle normalizer. [Solution] The technical features of the present invention for solving the above problem are as follows. 1. A normalizer of the collagen production and uptake cycle in skin fibroblasts, the normalizer having lycoperoside A as an active ingredient. 2. A normalizer of the elastin production and uptake cycle in skin fibroblasts, the normalizer having lycoperoside A as an active ingredient. 3. A normalizer of the ECM cycle in skin fibroblasts, the normalizer having lycoperoside A as an active ingredient.
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 36/81 - Solanaceae (famille de la pomme de terre), p. ex. tabac, Solanum ptycanthum, tomate, belladone, poivron ou datura
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61Q 19/00 - Préparations pour les soins de la peau
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
13.
BODY ODOR COMPONENT REDUCER AND BODY ODOR SUPPRESSOR USING SAME
[Problem] The purpose of the present invention is to provide a novel body odor component reducer. [Solution] The technical feature of the present invention for solving the above problem is described below. 1. A body odor component reducer having as an active ingredient a plant extract containing thymoquinone. 2. The body odor component reducer according to 1. above, wherein the plant extract is black cumin extract. 3. A body odor component reducer having thymoquinone as an active ingredient. 4. The body odor component reducer according to any one of 1. through 3. above, wherein the body odor component is at least one species selected from butyric acid and isovaleric acid. 5. A body odor component reducer having black cumin extract as an active ingredient. 6. A body odor component reducer characterized in that the body odor component is at least one species selected from butyric acid, isovaleric acid, diacetyl, and ammonia.
[Problem] To provide: an estrogen activity modulator which contains, as an active ingredient, a novel component that can exhibit an estrogen-like activity in the absence of estrogen and can act antagonistically in the presence of estrogen; and an agent for ameliorating unidentified complaints associated with a menstrual cycle, which is produced using the estrogen activity modulator. [Solution] The characteristic features of the present invention that can solve the problem reside in the followings. (1) An estrogen activity modulator which can exhibit an estrogen-like activity in the absence of estrogen and can exhibit an estrogen-inhibiting activity in the presence of estrogen, and which contains a pterocarpan compound as an active ingredient. (2) An estrogen activity modulator which can exhibit an estrogen-like activity in the absence of estrogen and can exhibit an estrogen-inhibiting activity in the presence of estrogen, and which contains, as an active ingredient, an Aguaje extract containing 8-hydroxyhomopterocarpan and lespeflorin G8. (3) An agent for ameliorating unidentified complaints associated with a menstrual cycle, which contains a pterocarpan compound as an active ingredient. (4) An agent for ameliorating unidentified complaints associated with a menstrual cycle, which contains, as an active ingredient, an Aguaje extract containing 8-hydroxyhomopterocarpan and lespeflorin G8.
A23L 33/11 - Stérols de plantes ou leurs dérivés, p. ex. phytostérols
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 35/00 - Aliments ou produits alimentaires non prévus par les groupes Leur préparation ou leur traitement
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 36/889 - Arecaceae, Palmae ou Palmaceae (famille du palmier), p. ex. dattier ou cocotier ou palmier nain
Provided are a novel use of 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-β-D-glucose (hereinafter abbreviated as "GHG") which is contained in a large amount in purple tea produced in Kenya (scientific name: Camellia sinensis, variety name: TRFK306); and a novel circadian rhythm regulator which is widely usable as medicines, beverages, foods and cosmetics. The circadian rhythm regulator according to the present invention is characterized by comprising GHG as an active ingredient having an effect of promoting the expression of Bmal1 gene. Also, the circadian rhythm regulator according to the present invention is characterized by comprising a GHG-containing extract derived from the purple tea produced in Kenya as an active ingredient having an effect of promoting the expression of Bmal1 gene.
This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
The present invention addresses the problem of providing a novel muscle energy metabolism activator, etc. and a composition that can be taken as a drug or a food. To solve the above problem, the technical features of the present invention are as follows. (1) A glucose transporter (GLUT4) gene expression promoter comprising as an active ingredient at least one member selected from among 5-hydroxy-3,7-dimethoxyflavone, techtochrysin, 3,7,4'-trimethyl kaempferol, retusine, pentamethyl quercetin, trimethyl apigenin, tetramethyl kaempferol and 5,7-dimethoxyflavone. (2) A glucose transporter (GLUT4) gene expression promoter comprising as an active ingredient at least one member selected from techtochrysin and 5,7-dimethoxyflavone. (3) A glucose transporter (GLUT4) gene expression promoter in muscle cells, said promoter comprising at least one compound represented by chemical formula (1) [wherein R1 and R2 represent each hydrogen or an alkyl group having 1-3 carbon atoms].
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
A61K 36/906 - Zingiberaceae (famille du gingembre)
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
19.
Methods for inhibiting advanced glycation end product production, inhibiting fibroblast apoptosis, and/or promoting human fibroblast-collagen grating formulation using cherry blossom and cherry leaf extract
Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains en extract of cherry tree (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active substance. The AGE production inhibitor or the like contains, as an active substance, at least one compound that is selected from among 1-O-(E)-Caffeoyl-β-D-glucopyranoside, 1-O-(E)-Coumaroyl-β-D-glucopyranoside, 1-O-(E)-Cinnamoyl-β-D-glucopyranoside, Kaempferol 3-O-β-D-glucopyranoside, Quercetin 3-O-β-D-glucopyranoside, Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside, and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside.
A61K 36/736 - Prunus, p. ex. prune, cerise, pêche, abricot ou amande
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A23G 3/36 - Sucreries, confiseries ou massepainProcédés pour leur fabrication caractérisés par la composition
A23G 4/06 - Chewing-gum caractérisé par la composition
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
C07H 13/04 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides carboxyliques comportant les radicaux carboxyle estérifiants liés à des atomes de carbone acycliques
A61Q 19/08 - Préparations contre le vieillissement
A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;
A61K 8/97 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base d’algues, de champignons, de lichens ou de plantesCosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de leurs dérivés
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Purple tea extracts containing 1, 2-di-O-Galloyl-4,6-O-hexahydroxydiphenoyl-beta-D-glucose used as an ingredient in the manufacture of [ beverages, ] nutritional supplements [, and foods ]
The objective of the present invention is to provide: a 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-b-D-glucose (hereinafter abbreviated as "GHG") containing composition that is a composition derived from a natural product and that contains a high concentration of GHG. The GHG-containing composition is characterized by being obtained from purple tea (scientific name: Camellia sinensis, cultivar name TRFK306) from Kenya, and having 3-10 mass% of GHG. The method for producing the GHG-containing composition is characterized by immersing the purple tea (scientific name: Camellia sinensis, cultivar name TRFK306) from Kenya in a polar solvent (including water), and then heating to reflux and extracting the GHG in the solvent.
A61K 8/97 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base d’algues, de champignons, de lichens ou de plantesCosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de leurs dérivés
Provided is a prophylactic/therapeutic agent for dry eye, which comprises a novel component capable of preventing the deterioration of a tear fluid secretion ability and also capable of inhibiting the generation of active oxygen in tear gland tissues. The prophylactic/therapeutic agent for dry eye according to the present invention contains a maqui berry extract as an active ingredient. The prophylactic/therapeutic agent for dry eye according to the present invention may contain, as an active ingredient, a delphinidin glycoside that is extracted from maqui berry. The prophylactic/therapeutic agent for dry eye according to the present invention may contain at least one component selected from delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, desirably delphinidin-3,5-diglucoside, as an active ingredient.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of diseases and conditions of the eye; dietary supplements for humans and animals; Plant extracts sold as a component ingredient of dietetic foods, namely, biscuits, cereal bars and cereal based snack foods and dietetic substances adapted for medical use; Plant extracts sold as a component ingredient food for babies; Plant extracts sold as a component ingredient of dietetic sugar substitutes for medical use
Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains an extract of cherry (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active ingredient. The AGE production inhibitor or the like contains, as an active ingredient, at least one compound that is selected from the group consisting of 1-O-(E)-caffeoyl-β-D-glucopyranoside, 1-O-(E)-coumaroyl-β-D-glucopyranoside, 1-O-(E)-cinnamoyl-β-D-glucopyranoside, kaempferol 3-O-β-D-glucopyranoside, quercetin 3-O-β-D-glucopyranoside, kaempferol 3-O-(6"-malonyl)-β-D-glucopyranoside, and quercetin 3-O-(6"-malonyl)-β-D-glucopyranoside.
A61K 8/97 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base d’algues, de champignons, de lichens ou de plantesCosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de leurs dérivés
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61Q 19/00 - Préparations pour les soins de la peau
C07H 13/04 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides carboxyliques comportant les radicaux carboxyle estérifiants liés à des atomes de carbone acycliques
[PROBLEMS] To provide: a novel agent having an inhibitory activity on hyaluronidase; and an anti-aging agent for the skin, an anti-inflammatory agent and others each of which comprises the agent. [MEANS FOR SOLVING PROBLEMS] Disclosed is a hyaluronidase inhibitor comprising a phenylethanoid glucoside as an active ingredient. The phenylethanoid glucoside preferably comprises at least one of echinacoside and acteoside. Also disclosed is a hyaluronidase inhibitor comprising an extract of a plant belonging to the family Cistanche as an active ingredient. The extract of a plant belonging to the family Cistanche is preferably isan extract from a stem of a plant Cistanche tubulosa. Each of the hyaluronidase inhibitors can be used in a pharmaceutical product for a mammal including human, an external preparation for the skin, a food/beverage or a feed for a mammal as an active ingredient of an anti-aging agent for the skin or an anti-inflammatory agent.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61Q 19/08 - Préparations contre le vieillissement
A61Q 19/10 - Préparations pour le nettoyage ou le bain
C07H 15/18 - Radicaux acycliques substitués par des carbocycles
